A novel prognostic six-CpG signature in glioblastomas.

ABSTRACT:

Aims

We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize individual treatment of patients with glioblastoma (GBM).

Methods

A six-CpG panel was identified by incorporating genome-wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk-score model. Different validation sets of GBMs and lower-grade gliomas and different statistical methods were implemented for prognostic evaluation. An integrative analysis of multidimensional TCGA data was performed to molecularly characterize different risk tumors.

Results

The six-CpG risk-score signature robustly predicted overall survival (OS) in all discovery and validation cohorts and in a treatment-independent manner. It als

SUBMITTER: Yin AA 

PROVIDER: S-EPMC6489960 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature